For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Paion UK Limited

Calculating rank

USPTO Granted Patents = 21

CIPO Patents = 1

EPO Patents = 8

Forward Citations = 119

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Gary Stuart Tilbrook (18 out of 18 patents)

Keith Borkett (8 out of 8 patents)

Hugh Wiltshire (8 out of 8 patents)

4. Karin Wilhelm-Ogunbiyi (8 out of 8 patents)

5. Louisa Jane Quegan (5 out of 6 patents)

6. Yuji Kawakami (3 out of 3 patents)

7. Tatsushi Murase (3 out of 3 patents)

8. Daisuke Tanaka (3 out of 3 patents)

9. Hideyuki Yoshiyama (3 out of 3 patents)

10. Shinitsu Kuwabe (3 out of 3 patents)

11. Andreas Schumacher (3 out of 7 patents)

12. Rene Emmenegger (2 out of 2 patents)

13. Louisa Jane Cubitt (2 out of 2 patents)

14. René Emmenegger (1 out of 1 patent)

15. Karl-Uwe Petersen (1 patent)

21 patents: Sort by Forward Citations

1. 12365684 - Short-acting benzodiazepine salts and their polymorphic forms (2025-07-22),

2. 12201637 - Dosing regimen for sedation with CNS 7056 (Remimazolam) (2025-01-21),

3. 10961250 - Short-acting benzodiazepine salts and their polymorphic forms (2021-03-30),

4. 10722522 - Dosing regimen for sedation with CNS 7056 (remimazolam) (2020-07-28),

5. 10472365 - Short-acting benzodiazepine salts and their polymorphic forms (2019-11-12),

6. 10414749 - Process for preparing 3-[(S)-7-bromo-2-((2-oxopropyl)amino)-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]propionic acid methyl ester (2019-09-17),

7. 10342800 - Dosing regimen for sedation with CNS 7056 (Remimazolam) (2019-07-09),

8. 10195210 - Dosing regimen for sedation with CNS 7056 (Remimazolam) (2019-02-05),

9. 10052334 - Dosing regimen for sedation with CNS 7056 (remimazolam) (2018-08-21),

10. 10000464 - Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiazepine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process (2018-06-19),

11. 9981941 - Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propionic acid methyl ester benzenesulfonate (2018-05-29),

12. 9914738 - Short-acting benzodiazepine salts and their polymorphic forms (2018-03-13),

13. 9827251 - Dosing regimen for sedation with CNS 7056 (remimazolam) (2017-11-28),

14. 9777007 - Short-acting benzodiazepine salts and their polymorphic forms (2017-10-03),

15. 9737547 - Dosing regimen for sedation with CNS 7056 (Remimazolam) (2017-08-22),

Company Overview

Paion UK Limited, based in Cambridge, specializes in the development of innovative pharmaceuticals, particularly in the field of anesthesia and sedation. The company focuses on creating advanced therapeutic solutions that enhance patient care and improve clinical outcomes. With a strong emphasis on research and development, Paion UK is dedicated to addressing unmet medical needs through its proprietary technologies and collaborations within the healthcare sector, contributing to the advancement of medical science in the UK and beyond.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

21 Patents

#51 in Cambridge

#850 in United Kingdom

#30,018 in the World

Cambridge, United Kingdom

Paion UK Limited

Forward Citations = 119

14 inventors:

Gary Stuart Tilbrook (18 out of 18 patents)

Keith Borkett (8 out of 8 patents)

Hugh Wiltshire (8 out of 8 patents)

4. Karin Wilhelm-Ogunbiyi (8 out of 8 patents)

5. Louisa Jane Quegan (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Paion UK Limited. Retrieved from https://idiyas.com/company/paion-uk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…